• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Interpace Diagnostics Announces Agreement with Acupath Laboratories

    Gabrielle Lakusta
    Mar. 28, 2018 09:02AM PST
    Biotech Investing

    Interpace Diagnostics (NASDAQ:IDXG) a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that the Company has entered into a Laboratory Services Agreement with Acupath Laboratories, Inc. based in Plainview, New York (Long Island) whereby Acupath’s Commercial team will be …

    Interpace Diagnostics (NASDAQ:IDXG) a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced that the Company has entered into a Laboratory Services Agreement with Acupath Laboratories, Inc. based in Plainview, New York (Long Island) whereby Acupath’s Commercial team will be selling ThyGenX® and ThyraMIR® as part of its menu for Endocrinologists, Endocrine Surgeons, and other physicians focused on the diagnosis and treatment of Thyroid cancer.

    As quoted in the press release:

    Founded in 1998, Acupath is a nationwide provider of in-network, sub-specialized anatomic pathology services focused on the following specialties; Endocrinology, Urology, Gastroenterology, Hematology / Oncology, Dermatology, Breast, Gynecology, Otolaryngology, and Podiatry. Acupath offers an extensive test menu across all service levels (global, TC only, client bill), has over 500 active clients, processes over 150,000 specimens annually, and is one of the leading providers of cutting edge FISH testing, which can assist in the detection and management of bladder cancer, prostate cancer (PTEN ERG), esophageal cancer, breast cancer (HER2), and cervical cancer (TERC). Terms of the Agreement were not disclosed.

    Click here to read the full press release.

    interpace diagnosticsdiagnostic testsbreast cancer
    The Conversation (0)

    Go Deeper

    AI Powered
    Radiopharm Theranostics

    Radiopharm Theranostics

    Biotech Outlook: World Edition

    Biotech Outlook: World Edition

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×